ArticleInfection and drug resistance2026
Evaluation of the Synergistic Activity of Anidulafungin with Isavuconazole, Voriconazole, Posaconazole, and Amphotericin B in
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Fifty clinical Results: High resistance rates were observed for fluconazole (72%) and amphotericin B (48%), whereas no isolates were resistant to echinocandins. In combination tests, interactions were predominantly indifferent (56-84%), followed by partial synergy (12-40%). A single instance of true synergy (FICI = 0.49) was noted with the anidulafungin-posaconazole combination in one isolate. Synergy rates (synergy + partial synergy) varied significantly across combinations (Fisher's exact test, p = 0.0044), with anidulafungin-azole combinations showing the highest rates (36-40%) compared to anidulafungin-amphotericin B (12%). No antagonism (FICI ≥ 4) was detected in any combination. Discussion: The predominance of indifferent interactions, with some partial synergy, suggests that combination therapy may not consistently offer a strong synergistic benefit for these isolates. This exploratory study characterizes the in vitro interaction landscape in our isolate collection, providing foundational data to guide future research and inform clinical decisions where treatment options are scarce.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.